• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ALA
Click for more information
0.00% 16.0¢

AROVELLA THERAPEUTICS LIMITED - Charts / Financials

Market Cap $168.2M  ! watchlist Created with Sketch. Add to my watchlist

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on... Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.More

refresh Created with Sketch. REFRESH
Last update - 14.08pm 27/09/2024 (20 minute delay) ?
Day
Open 16.0¢   Day High 16.5¢   Day Low 15.5¢
Daily Volume 877587
Bids   Sellers
Number Price Volume   Number Price Volume
8 15.5¢ 345704   1 16.0¢ 3094

Directors & Senior Management

Mr. Michael Baker Chief Executive Officer, Managing Director, Director
Mr. Tim Luscombe Chief Financial Officer, Company Secretary
Dr. Nicole van Der Weerden Chief Operating Officer
Dr. Thomas Duthy Non-Executive Chairman of the Board
Dr. Elizabeth Stoner Non-Executive Director
Dr. Debora Barton Non-Executive Independent Director
Mr. Gary Jonathan Phillips Independent Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
16.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $168.2M
Open High Low Value Volume
16.0¢ 16.5¢ 15.5¢ $140.9K 877.5K

Buyers (Bids)

No. Vol. Price($)
8 345704 15.5¢
 

Sellers (Offers)

Price($) Vol. No.
16.0¢ 3094 1
View Market Depth
Last trade - 15.21pm 27/09/2024 (20 minute delay) ?
Last
16.0¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
16.0¢ 16.0¢ 16.0¢ 174834
Last updated 14.08pm 27/09/2024 ?

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
KalGold rolls out detailed aeromagnetic survey across Pinjin project Kalgoorlie Gold Mining Ltd has begun a high-resolution aeromagnetic geophysical survey across the northern parts of the Pinjin project
5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core Strickland Metals Ltd has found an extensive zone of high-grade gold and base metals mineralisation at its Rogozna project
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
ACCC seeks Olam divestments before it can buy Namoi Cotton Australia's market regulator the ACCC has expressed further concerns about the potential takeover of Namoi Cotton by Olam Agri.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.